LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Articles
Onyx Pharmaceuticals Inc.
Headquarters:
South San Francisco, CA, United States
Website:
N/A
Year Founded:
1992
Status:
Acquired
BioCentury
|
Mar 25, 2024
Finance
Now a biotech pure-play, Avalon riding ‘sweat equity’ model to outsized returns
A smaller fund size can lead to a higher multiple — especially when a portfolio company such as Janux delivers promising early data
Read More
BioCentury
|
May 9, 2023
Management Tracks
Laronde’s Cagnoni to head R&D at Incyte
Plus: Glanzmann takes the helm at Grifols and updates from Frontier, Inceptor, Zevra and AceLink
Read More
BioCentury
|
May 3, 2023
Management Tracks
Culture and trust: How Cerevel’s Coles picked Renaud for CEO
Ahead of handful of milestones, former Translate Bio, Idenix CEO joining CNS company; Coles retaining chairman role
Read More
BioCentury
|
Mar 11, 2023
Emerging Company Profile
Opna Bio: targeting FMRP to treat cancer
Company’s other five small molecules come from CEO Gideon Bollag’s former company, Plexxikon
Read More
BioCentury
|
Jun 6, 2022
Deals
Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger
Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
Read More
BioCentury
|
Feb 24, 2022
Management Tracks
Philip to succeed Marrazzo at Spark
Plus LaCaze joins Mnemo and updates from Sumitomo, Veracyte, Totus and more
Read More
BioCentury
|
Jan 13, 2022
Management Tracks
Carino joins White House’s office of science and technology policy
Plus Foster becomes venture partner and updates from Norwest, TCR2, PTC and more
Read More
BioCentury
|
Nov 9, 2021
Data Byte
A tally of female CEOs at major biopharmas
Spoiler: you’ll soon need two hands to count them
Read More
BioCentury
|
Mar 4, 2021
Deals
Precision oncology readout becomes Five Prime’s denouement, driving $1.9B Amgen takeout
Target-validating data in genetically-defined cancer spurs buyout
Read More
BioCentury
|
Dec 2, 2020
Emerging Company Profile
Sofinnova’s Papiernik, Costa and Roche alum Garibaldi carve orphan neurology play Noema out of the pharma’s assets
Emerging Company Profile: Noema emerges from stealth with $59M to develop four clinical neurology programs in-licensed from Roche
Read More
Items per page:
10
1 - 10 of 911
Username
Elevio by Dixa